NCT01225549 - The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Asthma

Interventions

DRUG

AZD5423

Suspension for nebulisation once daily 7 days

DRUG

Budesonide 200 microgram

Dry powder for inhalation twice daily 7 days

DRUG

Placebo

Solution for nebulisation once daily 7 days

DRUG

Placebo

Solution for nebulisation once daily 7 days

Trial Locations (4)

Research Site, Calgary

Research Site, Hamilton

Research Site, Québec

Research Site, Saskatoon